Sonazoid Contrast-enhanced Ultrasound in Assessing Effectiveness of Neoadjuvant Chemotherapy in Breast Cancer Patients. - Trial NCT04657341
Access comprehensive clinical trial information for NCT04657341 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese PLA General Hospital and is currently Not yet recruiting. The study focuses on Ultrasound. Target enrollment is 1012 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Chinese PLA General Hospital
Timeline & Enrollment
N/A
Aug 01, 2020
Dec 01, 2021
Primary Outcome
Sonazoid contrast-enhanced ultrasound in assessing effectiveness of neoadjuvant chemotherapy in breast cancer patients.
Summary
Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of
 Sonazoid specific angiography and high mechanical index,the role of Sonazoid in assessing
 effectiveness of neoadjuvant chemotherapy in breast cancer patients was explored.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04657341
Non-Device Trial